Proton pump inhibitors and risk of colorectal cancer
Gut — Abrahami D, McDonald EG, Schnitzer ME, et al. | July 02, 2021
This study attempted to ascertain if proton pump inhibitors (PPIs) are correlated with an increased risk of colorectal cancer, compared with histamine-2 receptor antagonists (H2RAs).
Researchers used United Kingdom Clinical Practice Research Datalink to distinguish initiators of PPIs and H2RA from 1990 to 2018, with follow-up until 2019. They used Cox proportional hazards models to calculate marginal HRs and 95% CIs of colorectal cancer. The study enrolled 1,293,749 and 292 387 initiators of PPIs and H2RAs, respectively, followed for a median duration of 4.9 years. The findings suggest that prolonged use may be correlated with a modest increased risk of this malignancy, while any use of PPIs was not correlated with an increased risk of colorectal cancer compared with H2RAs.
Read the full article on Gut